Company intelligence / Profile preview
Grace Therapeutics, Inc.
Princeton, New Jersey, United Statesgracetx.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Phase 3
01
Overview
Grace Therapeutics has announced alignment with the FDA supporting the planned NDA submission for GTX-104. The company is developing novel formulations of existing drugs to improve performance with faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Novel drug formulationsInjectable formulationsOral mucosal sprayTopical spray
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Grace Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grace Therapeutics, Inc..